1. Scrip
  2. >>Business
  3. >>Deals

Lilly Wants To Gamble On Dice’s Oral IL-17 Drugs For Psoriasis

 
• By Joseph Haas

Lilly agrees to pay about $2.4bn to acquire Dice and its Phase IIb oral IL-17 inhibitor, as well as a discovery platform that has yielded a preclinical oral PD-L1 inhibitor.

Tumbling dice
Lilly is rolling the dice on oral IL-17 inhibitors in psoriasis • Source: Shutterstock

In a deal that may bring Eli Lilly and Company an oral alternative to blockbuster Taltz (ixekizumab) for psoriasis, the Indianapolis pharma unveiled an agreement on 20 June to acquire DICE Therapeutics, Inc. for approximately $2.4bn, the sixth-largest biopharmaceutical M&A deal of 2023.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.